Τόμος 28 (2010) – Τεύχος 2 – Άρθρο 12 – Επιθεώρηση Κλινικής Φαρμακολογίας και Φαρμακοκινητικής-Ελληνική Έκδοση – Volume 28 (2010) – Issue 2 – Article 12 – Epitheorese Klinikes Farmakologias και Farmakokinetikes-Greek Edition

Β. Α. Κόκκας

Α΄ Εργαστηριο Φαρμακολογίας, Ιατρική Σχολή, Αριστοτέλειο Πανεπιστήμιο Θεσσαλονίκης, Θεσσαλονίκη, Ελλάς

Β.Α. Κokkas

1^st Departement of Pharmacology, Medical School, Aristotle University, Thessaloniki, Hellas

2. Harvey R., Champe P., Mycek M.: Pharmacology. Lippincott-Raven Publ., New York, 1997

3. Rocco T., Fang J.: Pharmacotherapy of congestive heart failure. In: (Brunton L. et al., eds) Goodman and Gilman’s. The Pharmacological Basis of Therapeutics. Pp. 869-898, McGraw – Hill Comp, New York, 2006

4. Sabbah H.: The cellular and physiologic effects of beta blockers in heart. Clin. Cardiol. 22(Suppl.5): V16-20 (1999)

5. Wu A.: Should beta-blockers still be used as initial anti¬hypertensive agents in uncomplicated hypertension? Ann. Acad. Med. Singapore. 36: 962-963 (2007)

6. Lefkowitz R.: Historical review. A brief history and personal retrospective of seven transmembrane receptors. Trends Pharmacol. Sci. 25: 413-422 (2004)

7. Gilchrist A.: Modulating G-protein coupled receptors. From traditional pharmacology to allosterics. Trends Pharmacol. Sci. 28: 431-437 (2007)

8. Παπαδόπoυλoς Κ., Σακαντάμης Γ., Κόκκας Β.: H cAMP ως ενδoκυττάριoς αγγειoδιασταλτικός μεσoλαβητής. Epitheor. Klin. Farmakol. Farmakokonet. 5: 54-59 (1987)

9. Bourne H., Roberts J.: Drug receptor and pharmacodynamics. In (Katzung B., ed) Basic and clinical pharmacology. Pp. 9-32, Prentice-Hall Intern.Inc. Con. USA., 1995

10. Hoffman B.: Antihypertensive agents and the drug therapy of hypertension. In: (Brunton L. et al., eds) Goodman and Gilman’s. The Pharmacological Basis of Therapeutics. Pp 845-868, McGraw – Hill Comp., New York, 2006

11. Westfall Th., Westfall D.: Neurotransmission. In: (Brunton L. et al., eds) Goodman and Gilman’s. The Pharmacological Basis of Therapeutics. Pp. 137-182, McGraw – Hill Comp., New York, 2006

12. Westfall Th., Westfall D.: Adrenergic agonists and antagonists. In (Brunton L. et al., eds) Goodman and Gil-man’s. The Pharmacological Basis of Therapeutics. Pp. 237-298, McGraw – Hill Comp., New York, 2006

13. Molenaar P., Parsonage W.: Fundamental consideration of β-adrenoceptor subtypes in human heart failure. Trends Pharmacol. Sci. 26: 368-375 (2005)

14. Roden D.: Antiarrhythmic drugs. In In (Brunton L. et al., eds) Goodman and Gilman’s. The Pharmacological Basis of Therapeutics. Pp. 933-966, McGraw – Hill Comp., New York, 2006

15. Παπαδόπoυλoς Κ., Σακαντάμης Γ., Κόκκας Β.: O ρόλoς της cGMΡ στη ρύθμιση τoυ αγγειακoύ τόνoυ. Επιθ. Κλιν. Φαρμακoλ. Φαρμακoκιν. 5: 123-127 (1987)

16. Baumgarten G., Grohe C., Hoeft A., Knueferemann P.: Cytokines and heart failure. Anasthesiol. Intens. Notfal. Schmerz. 39: 197-203 (1996)

17. Khoynezhad A., Jatali Z., Tortolani A.: A synopsis of research in cardiac apoptosis and its application to congestive heart failure. Tex. Heart Inst J. 34: 352-359 (2007)

18. Κόκκας Β., Παπαδόπουλος Π.Κ., Παπαδόπουλος Κ.Λ.: Κυτταροκίνες και καρδιακή ανεπάρκεια. Εις: Κόκκας Β. και Παπαδόπουλος Κ.Λ., Εκδ.) Μοριακή Φαρμακολογία της Φλεγμονής με αναφορές στο καρδιαγγειακό σύστημα. Σελ. 263-286, Ιατρικές και Επιστημονικές και Εκδόσεις Σιώκη, Θεσσαλονίκη 2006

19. Michel T.: Treatment of myocardial ischemia. In (Brunton L. et al., eds) Goodman and Gilman’s. The Pharmacological Basis of Therapeutics. Pp. 823-845, McGraw – Hill Comp., New York, 2006

20. Skidgel R., Erdos G.: Histamine, bradykinin, and their antagonists. In (Brunton L. et al., eds) Goodman and Gil-man’s. The Pharmacological Basis of Therapeutics. Pp. 629-652, McGraw – Hill Comp., New York, 2006

21. Jackson E.: Renin and angiotensin. In (Brunton L. et al., eds) Goodman and Gilman’s. The Pharmacological Basis of Therapeutics. Pp. 823-845, 789-822, McGraw – Hill Comp., New York, 2006

22. Turner A., Hooper N.: The angiotensin coverting enzyme gene family. Genomics and Pharmacology. Trends Pharmacol. Sci. 23: 177-183 (2002)

23. Morris B., Zee R., Schrader A.: Different frequencies of angiotensin coverting enzyme genotypes in older hypertensive individuals. J. Clin. Invest. 94: 1085-1089 (1994)

24. Rakugi H., Kim D., Krieger J., Wangs D., Dzau V., Pratt R.: Induction of angiotensin coverting enzyme in the neointima after vascular injury. Possible role in restenosis. J. Clin. Invest. 93: 339-346 (1994)

25. Vanhoute P., Boulanger C., Illiano S., Nagao T., Vidal M., Mombouli J.: Endothelium-dependent effects of converting enzyme inhibitors. J. Cardiovasc. Pharmacol. 22(suppl.5): 10-16 (1993)

26. Dzau V.: Vascular angiotensin pathways: a new therapeutic target. J. Cardiovasc. Pharmacol. 10(Suppl.7): 9-16 (1987)

27. Johnston C.: Reninangiotensin system: a dual tissue and hormonal system for cardiovascular control. J. Hyper-tens. 10(Suppl.7): 13-26 (1992)

28. Dzau V., Pratt R.: Cardiac, vascular and intrarenal renin-angiotensin systems in normal physiology and dis-ease. In: Robertson J., Nicholls M. (eds): The Renin-An-giotensin System. Pp 42.1- 42.11, Mosby, London, 1993

29. Luscher T.: Angiotensin ACE inhibitors and endothelial control of vasomotor tone. Bas. Res. Cardiol. 88(Suppl. 1): 15-24 (1993)

30. Lonn E., Yusuf., Psa P., Montague T., Teo K., Benedict C., Pitt B.: Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection, Circulation 90: 2056-2069 (1994)

31. Guyton A., Hall J.: Textbook of Medical Physiology. Saunders W. Comp., Philadelphia USA, 1996

32. DeCasparo M., Catt K., Inagami T.: Angiotensin receptors. In: (Godfraind Th. et al., eds) The IUPHAR compendium of receptor characterization and classification. Pp. 81-84, IUPHAR Media Ltd, London, 1998

33. DeCasparo M., Husain A., Alexander W., Catt K., Chiu A., Drew M., Godfraind T., Harding I., Inagami T.,Timmermans P.: A proposed update of the nomenclature of angiotensin receptors. Hypertension 25:924-927 (1995)

34. Godfraind T., Elliot M., Catt K.: Drug therapy-angiotensin receptors and their antagonists. N. Engl. J. Med. 334: 1649-1654 (1996)

35. Griendling K., Ushiofucal M., Lassegue B., Alexander R.: Angiotensin II signaling in vascular smooth muscle – new concepts. Hypertension 29: 366-371 (1997)

36. Nakajima M., Hutchinson H., Fujinaga M., Hayashida W., Morishita R., Zhang I., Horiuchi M., Pratt R., Dzau V.: The angiotensin II type 2 (AT2) receptor antagonizes the growth effects of the AT1 receptor- Gain of function study using gene transfer, Proc. Nat. Acad. Sci. 92: 10663-10667 (1995)

37. Κόκκας Β., Παπακωνσταντίνου Ε., Παπαδόπουλος Κ.Λ.: Αγγειοτασίνη ΙΙ και δομή του αγγειακού τοιχώματος. Αρτηριακή Υπέρταση 7: 73-81 (1998)

38. Siragy H., Inagami T., Carey R.: NO and Cgmp mediate angiotensin AT2 receptor-induced renal rennin inhibition in young rats. Am. J. Physiol. Regul. Integr. Comp. Physiol. 293: R1461-R1467 (2007)

39. Papakonstantinou E., Karakioulakis G., Kokkas B., Papadopoulos C.L., Roth M.: Angiotensin II induced glycosaminoglycan synthesis by primary Human vascular smooth muscle cells is mediated by subtype-1 angiotensin II receptors. J. Cardiovasc. Pharmacol. 38: 715-728 (2001)

40. Diez.J.: A II antagonism prevents cardiomyocyte apoptosis and interstitial fibrosis in hypertensive heart disease. XXth Congress of the Eur. Soc. of Cardiol. Satelite Symposium: Exploring the potential of AII antagonist in cardiovascular management”.Vienna, 1998

41. Drexler H.: Interrelationship of AT1/AT2 receptors in cardiovascular function and remodeling. “XXth Congress of the Eur. Soc. of Cardiol.Satelite Symposium: Exploring the potential of ATII antagonist in cardiovascular management. Vienna, 1998

42. Myronidou M., Kokkas B., Kouyoumtzis A., Gregoriades N., Lourbopoulos A., Mylonas I., Papadopoulos C.L., Mirtsou-Fidani V.: Losartan increases NO production from the bovine aortic wall that is stimulated by angiotensin II. Eur. J. Inflammation. 3: 113-117 (2003)

43. Κόκκας Β.: Αγγειoδιασταλτικoί παράγoντες και γoυανυλoκυκλάσες. Επ. Κλιν. Φαρμακoλ. Φαρμακoκιν. 14: 276-281 (1997)

44. Josephson M., Zimetbaum P.: Ταχυαρρυθμίες. Εις: (Kasper D. et al., eds) Harrison. Εσωτερική Παθολογία. Pp. 1430-1447, Επιστημ. Εκδόσεις Παρισιάνου, Αθήνα. 2005

45. Jackson E.: Diuretics. K. Skidgel R., Erdos G.: Histamine, bradykinin, and their antagonists. In (Brunton L. et al., eds) Goodman and Gilman’s. The Pharmacological Basis of Therapeutics. Pp. 737-770, McGraw – Hill Comp., New York, 2006

46. Κόκκας Β.: Θέματα Μοριακής Φαρμακολογίας. University Studio Press, Θεσσαλονίκη (2003)

47. Berridge M.: Le calcium, un deuxième messager universel. Triangle 26: 71-82 (1986)

48. Hering St., Berjukow St., Aczel St.,Timin E.: Ca2+ channel block and inactivation: Common molecular determinants. Trends Pharmacol. Sci. 19: 439-443 (1988)

49. Κόκκας Β., Παπαδόπoυλoς Κ.: Ασβέστιo και αγγειακός τόνoς. Δυνατότητες φαρμακoλoγικής περέμβασης. Αρτηριακή Υπέρταση Φ20 : 4-6 (1988)

50. Μισσoπoύλoυ-Κόκκα Α.: Διακίνηση των ιόντων τoυ ασβεστίoυ δια των δυναμικoευαίσθητων διαύλων στην κυτταρική μεμβράνη των λείων μυϊκών ινών. Επιθ. Κλιν. Φαρμακoλ. Φαρμακoκιν. 13: 129-133 (1995)

51. Sancho J., Alvarez J., Montero M., Vilalobos C.: Ca2+ influx following receptor activation. Τrends Pharmacol. Sci. 13: 12-13 (1992)

52. Varadi G., Mori Y., Mikala G., Scwartz A.: Molecular determinants of Ca2+ channel function and drug action. Trends Pharmacol. Sci. 16: 43-49 (1995)

53. Kόκκας Β., Παπαδόπουλος K.Λ., Μισσοπούλου A.: Μηχανισμοί διακίνησης των ιόντων ασβεστίου σε κυτταρικό επίπεδο. Αρτηριακή Υπέρταση 5:61-68 (1996)

54. Karaki H.: Historical techniques: Cytosolic Ca2+ and contraction in smooth muscle. Trends Pharmacol. Sci. 25: 388-393 (2004)

55. Sorrentino V., Rizzuto R.: Molecular genetics of Ca2+ stores and intracellular Ca2+ signalling. Trends Pharmacol. Sci. 22: 461-466 (2001)

56. Hurwitz L., Fitzpatric D.: Localization of calcium pump activity in smooth muscles. Science 179: 354-355 (1973)

57. Sorrentino V., Rizzuto R.: Molecular genetics of Ca2+ stores and intracellular signalling. Trends Pharmacol. Sci. 22: 459-464 (2001)

58. Hasenfuss G.: Treatment of heart failure through stabilization of the cardiac ryanodine receptor. Circulation 107: 378-385 (2003)